|
|Section2= |Section3= }} URB597 is a relatively selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH).〔 〕〔 〕 FAAH is the primary degradatory enzyme for the endocannabinoid anandamide and, as such, inhibition of FAAH leads to an accumulation of anandamide in the CNS and periphery where it activates cannabinoid receptors. In pre-clinical laboratory tests researchers found URB597 increased the production of endocannabinoids resulting in measurable antidepressant and analgesic effects.〔 〕 URB597 is also known as KDS-4103. KDS-4103 is being developed by Kadmus Pharmaceuticals, Inc. for clinical trials in humans. Kadmus claims, on their website (linked below) that this class of compounds may have antidepressant, anti-anxiety, and pain-killing effects. ==See also== * FAAH * 4-Nonylphenylboronic acid * LY-2183240 * PF-04457845 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「URB597」の詳細全文を読む スポンサード リンク
|